According to transient elastography-derived data, non-alcoholic fatty liver disease (NAFLD)’s prevalence in the United States (US) has increased from 18% in 1988-1991 to an estimated 25-50% in recent years.
Previous studies investigating non-invasive tools for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, have demonstrated the clear diagnostic efficacy of liver stiffness measurement by vibration-controlled transient elastography (LSM-VCTE).
Generally, NASH and fibrosis correlate with the development of cirrhosis and other negative clinical outcomes. Treatments often aim to target inflammation, fibrosis, cell injury or metabolic dysregulation.
Despite its global prevalence of 25%, no pharmacotherapies have yet been approved to treat non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), its inflammatory subtype.
The spectrum of non-alcoholic fatty liver disease (NAFLD) is divisible into three stages: 1) NAFL, 2) non-alcoholic steatohepatitis (NASH), NAFLD’s progressive and inflammatory subtype, and 3) NAFLD or NASH with fibrosis, whose stages range from F0-4.
Join Dr Marat Fudim in this webinar as he delves into the complex interplay between non-alcoholic fatty liver disease (NAFLD) and heart failure. Uncover the paramount importance of comprehending the intersection between these two conditions in our pursuit of adequate healthcare solutions.
Hepatic microvascular dysfunction is central to the development and progression of nonalcoholic steatohepatitis (NASH), the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD).
Up to 30% of patients with non-alcoholic fatty liver disease (NAFLD) progress to non-alcoholic steatohepatitis (NASH), significantly increasing their risk of fibrosis and associated adverse outcomes. As such, ensuring the early identification of NAFLD and NASH in at-risk patients is a clinical priority.
Changing the terminology from NAFLD, non-alcoholic fatty liver disease, to MAFLD, metabolic dysfunction-associated fatty liver disease, has been an ongoing debate. MAFLD is based upon an individual having hepatic steatosis, as well as either type 2 diabetes mellitus, obesity (or being overweight) or if at a normal weight, two or more metabolic risk abnormalities.
Patients with non-alcoholic fatty liver disease (NAFLD) are at risk of progressing to inflammatory non-alcoholic steatohepatitis (NASH), a NAFLD subtype associated with fibrosis, cirrhosis, and hepatocellular carcinoma.
Discover the importance of a multistakeholder approach in NAFLD care, addressing the challenges of comorbidities, patient identification, and innovative strategies to improve treatment outcomes and healthcare coordination.
Explore the challenges and opportunities in the quest for a non-invasive diagnosis tool of non-alcoholic steatohepatitis (NASH) with insights from Dr Giada Sebastiani, associate professor of medicine at McGill University Health Center in Canada.